Sign In
Buy GSK
$50.67
-1.48 (-2.84%)
At Close: Jun 18, 2026
3 Top Cancer Treatment Stocks to Buy Now
06:30am, Wednesday, 17'th Jul 2024
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in reven
Why GSK (GSK) is a Top Value Stock for the Long-Term
10:41am, Tuesday, 16'th Jul 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
GSK CEO and Fleming Initiative Chair on Fighting Drug-Resistant 'Superbugs'
07:07am, Tuesday, 16'th Jul 2024
Emma Walmsley, CEO of GSK and Ara Darzi, Executive Director of the Fleming Initiative and Imperial College's Director of the Institute of Global Health Innovation, on their efforts to combat the rise
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
06:15am, Friday, 12'th Jul 2024
Undervalued pharma stocks can make good investments, whether during times of a booming economy or a faltering one. That is because people will still need medications and healthcare services regardless
Is GSK an Attractive Drug Stock to Add to Your Portfolio Now?
10:31am, Wednesday, 10'th Jul 2024
GSK plc GSK boasts a diversified base and presence in different geographical areas. The spin-off of the Consumer unit in 2022 has allowed it to focus on drug development.
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
07:00am, Monday, 08'th Jul 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
Will GSK Stock Rebound To Its 2022 Highs Of $47?
09:00am, Friday, 05'th Jul 2024
GSK plc stock (NYSE: GSK) trades at $38 per share, about 20% below its peak level of over $47 seen in April 2022. In contrast, its peer Bristol Myers Squibb stock (NYSE: BMY) saw a 48% decline over th
GSK Buys Flu, COVID mRNA Jab Rights From Partner CureVac
10:46am, Thursday, 04'th Jul 2024
GSK revamps its existing collaboration deal with partner CureVac, converting it from a collaboration deal into a licensing agreement related to mRNA vaccine candidates for COVID-19 and influenza.
GSK To Spend Up to $1.56B for Rights to Potential COVID-19, Flu Vaccines
01:46pm, Wednesday, 03'rd Jul 2024
Drug maker GSK (GSK) agreed to pay up to $1.56 billion for the rights to develop, manufacture, and market COVID-19 and influenza vaccines being worked on in collaboration with German biotechnology co
GSK Will Pay Up to $1.5 Billion for CureVac's mRNA Vaccines
10:18am, Wednesday, 03'rd Jul 2024
The deal represents a vote of confidence in the future of the mRNA-based vaccine market.
GSK Secures mRNA Vaccines For Bird Flu, COVID And Seasonal Flu From Struggling Biotech CureVac
07:59am, Wednesday, 03'rd Jul 2024
British Pharma giant GSK said on Wednesday it will pay as much as $1.5 billion to take control of several mRNA vaccines from vaccine developer CureVac, sending shares of the struggling German biotech
CureVac's stock soars on GSK's $1.56 billion deal for its COVID-19 and flu vaccines
07:53am, Wednesday, 03'rd Jul 2024
U.S.-listed shares of CureVac NV surged on Wednesday after GSK PLC announced an offer worth up to $1.56 billion (€1.44 billion) for the rights to the German biopharmaceutical's COVID-19 and flu vacc
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
05:21am, Wednesday, 03'rd Jul 2024
For investors with a long-term mindset, there's never a wrong time to put your money to work on Wall Street. Most online brokers have eliminated minimum deposit requirements and commission fees for co
GSK takes full control of flu vaccine programme in €1.45bn deal
03:11am, Wednesday, 03'rd Jul 2024
GSK PLC (LSE:GSK, NYSE:GSK) said it will take effective control of a collaboration to create new mRNA vaccines for influenza and COVID-19 under a €1.45 billion deal. Under a new agreement with Ge
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
02:40am, Wednesday, 03'rd Jul 2024
GSK acquires full rights to develop, manufacture and commercialize globally mRNA candidate vaccines for influenza and COVID-19, including combinations CureVac receives €400 million upfront and up to
